<!DOCTYPE html
  PUBLIC "-//W3C//DTD HTML 4.01//EN">
<html xmlns:gc="http://docs.oasis-open.org/codelist/ns/genericode/1.0/"><head xmlns="http://www.w3.org/1999/xhtml"><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"></meta><meta charset="utf-8"></meta><meta name="viewport" content="width=device-width, initial-scale=1"></meta><meta name="documentId" content="aeb4ec67-8764-4b72-b7a5-0bae88db11a3"></meta><meta name="documentSetId" content="dd76ec67-9064-4b72-b7a5-0bae88db11a3"></meta><meta name="documentVersionNumber" content="1"></meta><meta name="documentEffectiveTime" content="20170101"></meta><title>Twynsta (Telmisartan / Amlodipine (as Amlodipine Besylate)) Tablets</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/css/bootstrap.min.css" integrity="sha384-Vkoo8x4CGsO3+Hhxv8T/Q5PaXtkKtu6ug5TOeNV6gBiFeWPGFN9MuhOf23Q9Ifjh" crossorigin="anonymous"></link><link rel="stylesheet" href="https://cease353.github.io/xtest/current/spl_canada.css"></link><style>
				/* ScrollSpy, Stickiness/Affix, and French Navigation Reduction */
			  
				html {
					scroll-behavior: smooth;
				}
								
				.sticky {
					position: -webkit-sticky;
					position: sticky;
					top: 0;
				}

/* pmh - WeasyPrint Bootstrap 4 column hack - see https://github.com/Kozea/WeasyPrint/issues/697:
@media print {
	.col, *[class^="col-"] {		
		max-width: none !important; 
	}
} */


/* pmh - I do not think this is going to work: */
/*a::after {
content: ", page " target-counter(attr(href), page );
}
.frontmatter a::after { content: leader('.') target-counter(attr(href url), page, lower-roman) }
.bodymatter a::after { content: leader('.') target-counter(attr(href url), page, decimal) }
@page { counter-increment: page }
#pageNumber { content: counter(page) } */

				
				</style></head><body data-spy="scroll" data-target="#navigation-sidebar" data-offset="1"><div class="bg-aurora-accent1 hide-in-print"><h2 class="text-white text-center p-2">Twynsta (Telmisartan / Amlodipine (as Amlodipine Besylate)) Tablets</h2></div><div class="container-fluid position-relative" id="content"><div class="row h-100"><aside xmlns="http://www.w3.org/1999/xhtml" class="hide-in-print mb-2" id="left"><div class="sticky-top sticky d-none d-md-block hide-in-print" id="side"><section class="card"><h5 class="card-header text-white bg-aurora-accent1">TABLE OF CONTENTS</h5><div style="transform: scaleX(-1);" id="navigation-scrollbar"><ul class="navbar-nav" id="navigation-sidebar" style="transform: scaleX(-1); "><li class="nav-item"><a href="#drop-f6ac9de5-be91-442c-9579-5bc9ebd36902" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PRODUCT DETAILS</a><ul id="drop-f6ac9de5-be91-442c-9579-5bc9ebd36902" class="navbar-nav small collapse"><li class="nav-item"><a href="#company-details" class="nav-link active">COMPANY DETAILS</a></li><li class="nav-item"><a href="#product-1" class="nav-link">Product #1 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			40&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			5&nbsp;
			mg&nbsp;
		TABLET</a></li><li class="nav-item"><a href="#product-2" class="nav-link">Product #2 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			40&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			10&nbsp;
			mg&nbsp;
		TABLET</a></li><li class="nav-item"><a href="#product-3" class="nav-link">Product #3 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			80&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			5&nbsp;
			mg&nbsp;
		TABLET</a></li><li class="nav-item"><a href="#product-4" class="nav-link">Product #4 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			80&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			10&nbsp;
			mg&nbsp;
		TABLET</a></li></ul></li><li class="nav-item"><a href="#d8d30d86-e343-48f4-9cec-524834b3803b" class="nav-link nav-top">TITLE PAGE</a></li><li class="nav-item"><a href="#a7cee5c8-7ee9-4fd2-884e-7a50c06b27e1" class="nav-link nav-top">RECENT MAJOR LABEL CHANGES</a></li><li class="nav-item"><a href="#drop-c16a947e-e2be-45c0-8b2e-15d0d0eebea8" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART I: HEALTH PROFESSIONAL INFORMATION</a><ul id="drop-c16a947e-e2be-45c0-8b2e-15d0d0eebea8" class="navbar-nav small collapse"><li class="nav-item"><a href="#a52ea4fa-2b79-4dbc-8d99-6843adc2dec8" class="nav-link">1 INDICATIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#f2aa7e0e-2042-4a4c-a783-9ad4e8717a32" class="nav-link">1.1 PEDIATRICS</a></li><li class="nav-item"><a href="#be75cfb9-3132-4903-800b-267427388a13" class="nav-link">1.2 GERIATRICS</a></li></ul></li><li class="nav-item"><a href="#be75cfb9-3132-4903-801b-267427388a13" class="nav-link">2 CONTRAINDICATIONS</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267427398a13" class="nav-link">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</a></li><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267727398a13" class="nav-link">4 DOSAGE AND ADMINISTRATION</a><ul class="navbar-nav"><li class="nav-item"><a href="#be75cfb9-3131-4103-800b-267727398a13" class="nav-link">4.1 DOSING CONSIDERATIONS</a></li><li class="nav-item"><a href="#b3d876c1-c36c-4ed5-8993-c507e3ab9f2e" class="nav-link">4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f3a" class="nav-link">4.3 ADMINISTRATION</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f4a" class="nav-link">4.4 RECONSTITUTION</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f5a" class="nav-link">4.5 MISSED DOSE</a></li></ul></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f6a" class="nav-link">5 OVERDOSAGE</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-a12dba105f7a" class="nav-link">6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</a></li><li class="nav-item"><a href="#a47ddb1b-4d6c-4f0b-97d7-7feb718963e1" class="nav-link">7 WARNINGS AND PRECAUTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#e7f348e6-c9c4-43d5-950e-2a754092a1fa" class="nav-link">7.1 SPECIAL POPULATIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#e94dc526-7275-40e3-8386-c43f0018b303" class="nav-link">7.1.1 PREGNANT WOMEN</a></li><li class="nav-item"><a href="#a63c33a5-e08a-472c-b8a2-b12dbd115f7a" class="nav-link">7.1.2 BREAST-FEEDING</a></li><li class="nav-item"><a href="#db71c420-7743-43da-8386-5463a89b0f93" class="nav-link">7.1.3 PEDIATRICS</a></li><li class="nav-item"><a href="#ee781ef0-be0c-406f-95f9-1122d8bf9968" class="nav-link">7.1.4 GERIATRICS</a></li></ul></li></ul></li><li class="nav-item"><a href="#fa8186fe-cc41-11e9-a32f-2a2ae2dbcce4" class="nav-link">8 ADVERSE REACTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#b238395c-cc41-11e9-a32f-2a2ae2dbdce4" class="nav-link">8.1 ADVERSE REACTION OVERVIEW</a></li><li class="nav-item"><a href="#a98b942a-cc41-11e9-a32f-2a2ae2dbcce4" class="nav-link">8.2 CLINICAL TRIAL ADVERSE REACTIONS</a></li><li class="nav-item"><a href="#a0065926-cc41-11e9-a32f-2a2ae2dbcce4" class="nav-link">8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS</a></li><li class="nav-item"><a href="#a6d30f16-cc41-11e9-a32f-2a2ae2dbcce4" class="nav-link">8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b32dbd215f7a" class="nav-link">8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS)</a></li><li class="nav-item"><a href="#c2b713f2-cc40-11e9-a32f-2a2ae2dbcce4" class="nav-link">8.6 POST-MARKET ADVERSE REACTIONS</a></li></ul></li><li class="nav-item"><a href="#f3daf956-cc41-11e9-a32f-2a2ae2dbcce4" class="nav-link">9 DRUG INTERACTIONS</a><ul class="navbar-nav"><li class="nav-item"><a href="#be75cfb9-3131-4903-800b-267527398a13" class="nav-link">9.1 SERIOUS DRUG INTERACTIONS BOX</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8a2-b14dbd315f7a" class="nav-link">9.2 OVERVIEW</a></li><li class="nav-item"><a href="#a63c33a5-e08a-473c-b8d2-b14dbd315f7a" class="nav-link">9.3 DRUG-DRUG INTERACTIONS</a></li><li class="nav-item"><a href="#a63c33a5-e0aa-473c-b8a2-b14dbd315f7a" class="nav-link">9.4 DRUG-FOOD INTERACTIONS</a></li><li class="nav-item"><a href="#a63c33a5-e08a-47bc-b8d2-b14dbd315f7a" class="nav-link">9.5 DRUG-HERB INTERACTIONS</a></li><li class="nav-item"><a href="#be78cfb9-3131-4903-800b-267527398a13" class="nav-link">9.6 DRUG-LABORATORY TEST INTERACTIONS</a></li><li class="nav-item"><a href="#a63c33a5-e0aa-473c-b8a2-b14dcd315f7a" class="nav-link">9.7 DRUG-LIFESTYLE INTERACTIONS</a></li></ul></li><li class="nav-item"><a href="#fa324c26-b939-4c3a-901d-516ccc314522" class="nav-link">10 ACTION AND CLINICAL PHARMACOLOGY</a><ul class="navbar-nav"><li class="nav-item"><a href="#aa324c26-b939-4c3a-901e-516ccc314522" class="nav-link">10.1 MECHANISM OF ACTION</a></li><li class="nav-item"><a href="#da324c26-b939-4d3a-901e-516ccc314522" class="nav-link">10.2 PHARMACODYNAMICS</a></li><li class="nav-item"><a href="#ba324c26-b939-4d4a-901e-516ccc314522" class="nav-link">10.3 PHARMACOKINETICS</a></li></ul></li><li class="nav-item"><a href="#aa324d26-c939-443a-901e-526dcc314522" class="nav-link">11 STORAGE, STABILITY AND DISPOSAL</a></li><li class="nav-item"><a href="#aa325d26-c939-443a-901e-526dcc314522" class="nav-link">12 SPECIAL HANDLING INSTRUCTIONS</a></li></ul></li><li class="nav-item"><a href="#drop-b6a947eb-e2be-45c0-8b2e-15d0d0eebed8" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART II: SCIENTIFIC INFORMATION</a><ul id="drop-b6a947eb-e2be-45c0-8b2e-15d0d0eebed8" class="navbar-nav small collapse"><li class="nav-item"><a href="#c2875272-8229-4c12-919e-827854dcd76a" class="nav-link">13 PHARMACEUTICAL INFORMATION</a></li><li class="nav-item"><a href="#a3287527-8229-4c12-919e-827854ddd76a" class="nav-link">14 CLINICAL TRIALS</a><ul class="navbar-nav"><li class="nav-item"><a href="#e3287527-8229-4c12-919e-827854ddd78a" class="nav-link">14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS</a></li><li class="nav-item"><a href="#a2875272-8229-4c12-919e-827854ddd78a" class="nav-link">14.2 STUDY RESULTS</a></li><li class="nav-item"><a href="#a4287527-8229-4c12-919e-827954ddd78a" class="nav-link">14.3 COMPARATIVE BIOAVAILABILITY STUDIES</a></li></ul></li><li class="nav-item"><a href="#a2875272-8229-4c12-a19e-827954ddd78a" class="nav-link">15 MICROBIOLOGY</a></li><li class="nav-item"><a href="#a42a7527-8229-4c12-a19e-827954ddd78a" class="nav-link">16 NON-CLINICAL TOXICOLOGY</a></li><li class="nav-item"><a href="#b8a4d498-0fc3-4e44-b4b6-550140d4de5d" class="nav-link">17 SUPPORTING PRODUCT MONOGRAPHS</a></li></ul></li><li class="nav-item"><a href="#drop-baa4d498-0fc3-4e44-b4b6-550140d4de5d" class="nav-link nav-top dropdown-toggle" data-toggle="collapse">PART III: PATIENT MEDICATION INFORMATION</a><ul id="drop-baa4d498-0fc3-4e44-b4b6-550140d4de5d" class="navbar-nav small collapse"><li class="nav-item"><a href="#baa4d498-0fc3-4e44-b4b6-550140dde5d" class="nav-link">BRAND NAME</a></li><li class="nav-item"><a href="#baa4d498-0fc3-4e44-b4b6-550140d4e5d" class="nav-link">PROPER NAME IN FINAL DOSAGE FORMS</a></li><li class="nav-item"><a href="#baa4d498-0gc3-4e44-bcb6-550140d4de5d" class="nav-link">WHAT IS THIS MEDICATION USED FOR?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e44-bcb6-550140d4de5d" class="nav-link">HOW DOES THIS MEDICATION WORK?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e44-bcb6-55013024de5d" class="nav-link">WHAT ARE THE INGREDIENTS IN THIS MEDICATION?</a></li><li class="nav-item"><a href="#bca4d498-0gc3-4e54-bcb6-550130d4de5d" class="nav-link">THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:</a></li><li class="nav-item"><a href="#bca4c498-0gc3-4e44-bcb6-550134d4de5d" class="nav-link">DO NOT USE THIS MEDICATION IF:</a></li><li class="nav-item"><a href="#b6b37351-bbc9-46d9-b148-27ba3cb0a75e" class="nav-link">TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU:</a></li><li class="nav-item"><a href="#edac0d6f-3c91-48b5-99c0-e0f940925d37" class="nav-link">OTHER WARNINGS YOU SHOULD KNOW ABOUT:</a></li><li class="nav-item"><a href="#f040bb1e-8989-42c8-82dc-53a855e88f0f" class="nav-link">TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.</a></li><li class="nav-item"><a href="#bca40498-0gc3-4e44-bcb6-550134d4de5d" class="nav-link">THE FOLLOWING MAY INTERACT WITH THIS MEDICATION:</a></li><li class="nav-item"><a href="#e23321cd-5111-4aa3-b650-74f93bcda261" class="nav-link">HOW TO TAKE THIS MEDICATION:</a></li><li class="nav-item"><a href="#cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7" class="nav-link">USUAL DOSE:</a></li><li class="nav-item"><a href="#beaaa5b8-6693-4d4c-a897-fa5c9562b1be" class="nav-link">OVERDOSE:</a></li><li class="nav-item"><a href="#ffd59b8d-fe66-4d86-a54f-0613d4168199" class="nav-link">MISSED DOSE:</a></li><li class="nav-item"><a href="#cb61f530-b95a-4047-b8ea-861c5a7a05e8" class="nav-link">WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION?</a></li><li class="nav-item"><a href="#ee37dfa5-6d8c-4490-b4a5-c6f2d73aa041" class="nav-link">SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM</a></li><li class="nav-item"><a href="#c9d75711-2ce9-451e-aa51-91026ec1555e" class="nav-link">STORAGE:</a></li><li class="nav-item"><a href="#f6693e7a-21c9-492f-833b-4e8f3911d3a5" class="nav-link">IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:</a></li></ul></li></ul></div></section></div></aside><main class="col"><div class="container-fluid" id="main"><div class="row position-relative"><div class="col"><section class="card mb-2 hide-in-print" id="f6ac9de5-be91-442c-9579-5bc9ebd36902"><h5 class="card-header text-white bg-aurora-accent1">PRODUCT DETAILS</h5><div id="product-accordion"><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="company-details"><h6 class="card-header p-0 bg-aurora-accent2"><button class="btn bg-aurora-accent2 text-white text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-company-details" aria-expanded="true" aria-controls="collapse-company-details">COMPANY DETAILS</button></h6><div id="collapse-company-details" class="collapse show spl" data-parent="#product-accordion"><table xmlns="" width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Market Authorization Holder -&nbsp;</span>BOEHRINGER INGELHEIM (CANADA) LTD LTEE (3617)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>5180 South Service Road</td></tr><tr><td>Burlington,&nbsp;Ontario,&nbsp;L7L 5H4</td></tr><tr><td>CANADA</td></tr></table></td><td class="formItem"><div>Tel: +18002635103</div><div>Email: test@boehringer.ca</div><div>Web: https://www.boehringer-ingelheim.ca</div></td></tr></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-1"><h6 class="card-header p-0 bg-aurora-accent2"><button class="btn bg-aurora-accent2 text-white text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-1" aria-expanded="true" aria-controls="collapse-product-1">Product #1 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			40&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			5&nbsp;
			mg&nbsp;
		TABLET</button></h6><div id="collapse-product-1" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371022</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">40&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">5&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A1</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>1234<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-2"><h6 class="card-header p-0 bg-aurora-accent2"><button class="btn bg-aurora-accent2 text-white text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-2" aria-expanded="true" aria-controls="collapse-product-2">Product #2 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			40&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			10&nbsp;
			mg&nbsp;
		TABLET</button></h6><div id="collapse-product-2" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371030</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">40&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">10&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A2</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>2<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-3"><h6 class="card-header p-0 bg-aurora-accent2"><button class="btn bg-aurora-accent2 text-white text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-3" aria-expanded="true" aria-controls="collapse-product-3">Product #3 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			80&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			5&nbsp;
			mg&nbsp;
		TABLET</button></h6><div id="collapse-product-3" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371049</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">80&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">5&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A3</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>3<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section xmlns="http://www.w3.org/1999/xhtml" class="card m-2" id="product-4"><h6 class="card-header p-0 bg-aurora-accent2"><button class="btn bg-aurora-accent2 text-white text-left w-100" type="button" data-toggle="collapse" data-target="#collapse-product-4" aria-expanded="true" aria-controls="collapse-product-4">Product #4 Twynsta 
		(telmisartan/amlodipine), 		
		TELMISARTAN&nbsp;
			80&nbsp;
			mg&nbsp;
		/ AMLODIPINE&nbsp;
			10&nbsp;
			mg&nbsp;
		TABLET</button></h6><div id="collapse-product-4" class="collapse spl" data-parent="#product-accordion"><table xmlns="" class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371057</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">80&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">10&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A4</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>4<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section></div></section><section class="card mb-2 force-page-break" id="d8d30d86-e343-48f4-9cec-524834b3803b"><h5 class="card-header text-white bg-aurora-accent1">TITLE PAGE</h5><div class="spl title-page p-3"><h2>TITLE</h2><p class="First"><span class="Sup">Pr</span>Twynsta<span class="Sup">Â®</span><br> Telmisartan / Amlodipine (as Amlodipine Besylate) Tablets <br> Tablets 40/5
                  mg, 40/10 mg, 80/5 mg, 80/10 mg <br> Angiotensin II AT1 Receptor Blocker /
                  Calcium Channel Blocker </p></div><div class="spl container p-5"><div class="row"><div class="col-6"><h2>COMPANY NAME AND ADDRESS</h2><p class="First"> Boehringer Ingelheim (Canada) Ltd. <br> 5180 South Service Road <br>
                  Burlington, Ontario <br> L7L 5H4 </p></div><div class="col-6"><h2>DATE OF INITIAL APPROVAL</h2><p class="First">December 20, 2018</p><h2>DATE OF REVISION</h2><p class="First">December 20, 2019</p><h2>CONTROL NUMBER</h2><p class="First">125785</p></div></div></div></section><section class="card mb-2" id="a7cee5c8-7ee9-4fd2-884e-7a50c06b27e1"><h5 class="card-header text-white bg-aurora-accent1">RECENT MAJOR LABEL CHANGES</h5><div class="spl recent-changes"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="60007" id="a7cee5c8-7ee9-4fd2-884e-7a50c06b27e1"><a name="a7cee5c8-7ee9-4fd2-884e-7a50c06b27e1"></a><a name="section-ECENT MAJOR LABEL CHANGESIndications (1)05/2018Indications, Pediatrics (1.1)05/2018Contraindications (2)04/2018Serious Warning and Precautions Box (3), Lactic Acidosis and Severe Hepatomegaly with Steatosis [Removed]05/2018Dosage and Administration, Recommended Dose and Dose Adjustment (4.3)08/2018Warnings and Precautions, Endocrine and Metabolism (7)05/2018"></a><p></p><h1 xmlns="">RECENT MAJOR LABEL CHANGES</h1><a xmlns="" name="t6"></a><table xmlns="" width="100%"><tbody class="Headless"><tr class="First"><td>Indications (1)</td><td>05/2018</td></tr><tr><td>Indications, Pediatrics (1.1)</td><td>05/2018</td></tr><tr><td>Contraindications (2)</td><td>04/2018</td></tr><tr><td>Serious Warning and Precautions Box (3), Lactic Acidosis and Severe Hepatomegaly with Steatosis [Removed]</td><td>05/2018</td></tr><tr><td>Dosage and Administration, Recommended Dose and Dose Adjustment (4.3)</td><td>08/2018</td></tr><tr class="Last"><td>Warnings and Precautions, Endocrine and Metabolism (7)</td><td>05/2018</td></tr></tbody></table></div></div></section><section class="card mb-2 pb-2" id="c16a947e-e2be-45c0-8b2e-15d0d0eebea8"><h5 class="card-header text-white bg-aurora-accent1">PART I: HEALTH PROFESSIONAL INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="60008" id="c16a947e-e2be-45c0-8b2e-15d0d0eebea8"><a name="c16a947e-e2be-45c0-8b2e-15d0d0eebea8"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text "></a><p></p><h1 xmlns="">PART I: HEALTH PROFESSIONAL INFORMATION</h1><div class="Section" data-sectionCode="60009" id="a52ea4fa-2b79-4dbc-8d99-6843adc2dec8"><a name="a52ea4fa-2b79-4dbc-8d99-6843adc2dec8"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text"></a><p></p><h2 xmlns="">1 INDICATIONS</h2><p xmlns="" class="First"> sample text 
				</p><div class="Section" data-sectionCode="60010" id="f2aa7e0e-2042-4a4c-a783-9ad4e8717a32"><a name="f2aa7e0e-2042-4a4c-a783-9ad4e8717a32"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text1.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. "></a><p></p><h3 xmlns="">1.1 PEDIATRICS</h3><p xmlns="" class="First"> TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment
                      of mild to moderate essential hypertension for whom combination therapy is
                      appropriate. <br><br> TWYNSTA is not indicated for initial therapy (see DOSAGE AND
                        ADMINISTRATION).<br><br> Patients should be titrated on individual drugs. If the fixed dose
                      combination represents the dose and dosing frequency determined by this
                      titration, the use of TWYNSTA may be more convenient in the management of
                      patients. If during maintenance therapy dosage adjustment is necessary, it is
                      advisable to use the individual drugs. <br><br><span class="Bold">Geriatrics:</span><br> No dose adjustment is necessary for elderly patients. It should be
                      recognized, however, that greater sensitivity in some older individuals cannot
                      be ruled out. <br><br><span class="Bold">Pediatrics (&lt; 18 years of age):</span><br>
                      TWYNSTA is not recommended for use in patients aged below 18 years due to a
                      lack of data on safety and efficacy. </p></div><div class="Section" data-sectionCode="60011" id="be75cfb9-3132-4903-800b-267427388a13"><a name="be75cfb9-3132-4903-800b-267427388a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text1.2 GERIATRICSsample text"></a><p></p><h3 xmlns="">1.2 GERIATRICS</h3><p xmlns="" class="First">sample text</p></div></div><div class="Section" data-sectionCode="60012" id="be75cfb9-3132-4903-801b-267427388a13"><a name="be75cfb9-3132-4903-801b-267427388a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 2 CONTRAINDICATIONS sample text "></a><p></p><h2 xmlns="">2 CONTRAINDICATIONS</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60013" id="be75cfb9-3131-4903-800b-267427398a13"><a name="be75cfb9-3131-4903-800b-267427398a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                "></a><p></p><h2 xmlns="">3 SERIOUS WARNINGS AND PRECAUTIONS BOX</h2><a xmlns="" name="t4"></a><table xmlns="" border="1" cellpadding="6" cellspacing="1" width="80%"><caption><span>Serious Warnings and Precautions</span></caption><tbody class="Headless"><tr class="First Last"><td><span class="Bold">When used in pregnancy, angiotensin receptor (AT1)
                          blockers (ARB) can cause injury or even death of the developing fetus.
                          When pregnancy is detected, TWYNSTA should be discontinued as soon as
                          possible (see WARNINGS AND PRECAUTIONS, Special Populations).</span></td></tr></tbody></table><p xmlns="" class="First"><span class="Bold"><span class="Underline"> General </span></span><br>A case of rare but fatal angioedema had occurred in a patient who
                  had been medicated for about 6 months with telmisartan, one of the active
                  components of TWYNSTA. The Autopsy Report described evidence of edema of the
                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in
                  the context of approximately 5.2 million patient-years exposure to telmisartan
                  annually. <br><br> If laryngeal stridor or angioedema of the face, extremities,
                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the
                  patient treated appropriately in accordance with accepted medical care, and
                  carefully observed until the swelling disappears. In instances where swelling is
                  confined to the face and lips, the condition generally resolves without treatment,
                  although antihistamines may be useful in relieving symptoms. Where there is
                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,
                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous
                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing
                    Adverse Drug Reactions; Telmisartan). <br><br> Patients with a
                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated
                  with TWYNSTA (see ADVERSE
                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune
                    System Disorders, Angioedema and ADVERSE REACTIONS - Post
                      Marketing Adverse Drug Reactions; Telmisartan).<br><br><span class="Bold">Beta-blocker withdrawal:</span> TWYNSTA gives no
                  protection against the dangers of abrupt beta- blocker withdrawal and such
                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.
                </p></div><div class="Section" data-sectionCode="60014" id="be75cfb9-3131-4903-800b-267727398a13"><a name="be75cfb9-3131-4903-800b-267727398a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text "></a><p></p><h2 xmlns="">4 DOSAGE AND ADMINISTRATION</h2><p xmlns="" class="First"> sample text </p><div class="Section" data-sectionCode="60015" id="be75cfb9-3131-4103-800b-267727398a13"><a name="be75cfb9-3131-4103-800b-267727398a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 4.1 DOSING CONSIDERATIONS sample text "></a><p></p><h3 xmlns="">4.1 DOSING CONSIDERATIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60016" id="b3d876c1-c36c-4ed5-8993-c507e3ab9f2e"><a name="b3d876c1-c36c-4ed5-8993-c507e3ab9f2e"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text "></a><p></p><h3 xmlns="">4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60017" id="a63c33a5-e08a-472c-b8a2-a12dba105f3a"><a name="a63c33a5-e08a-472c-b8a2-a12dba105f3a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 4.3 ADMINISTRATIONsample text"></a><p></p><h3 xmlns="">4.3 ADMINISTRATION</h3><p xmlns="" class="First">sample text</p></div><div class="Section" data-sectionCode="60018" id="a63c33a5-e08a-472c-b8a2-a12dba105f4a"><a name="a63c33a5-e08a-472c-b8a2-a12dba105f4a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 4.4 RECONSTITUTION sample text "></a><p></p><h3 xmlns="">4.4 RECONSTITUTION</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60019" id="a63c33a5-e08a-472c-b8a2-a12dba105f5a"><a name="a63c33a5-e08a-472c-b8a2-a12dba105f5a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 4.5 MISSED DOSE sample text "></a><p></p><h3 xmlns="">4.5 MISSED DOSE</h3><p xmlns="" class="First"> sample text </p></div></div><div class="Section" data-sectionCode="60020" id="a63c33a5-e08a-472c-b8a2-a12dba105f6a"><a name="a63c33a5-e08a-472c-b8a2-a12dba105f6a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 5 OVERDOSAGE sample text "></a><p></p><h2 xmlns="">5 OVERDOSAGE</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60021" id="a63c33a5-e08a-472c-b8a2-a12dba105f7a"><a name="a63c33a5-e08a-472c-b8a2-a12dba105f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text"></a><p></p><h2 xmlns="">6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</h2><p xmlns="" class="First">sample text</p></div><div class="Section" data-sectionCode="60022" id="a47ddb1b-4d6c-4f0b-97d7-7feb718963e1"><a name="a47ddb1b-4d6c-4f0b-97d7-7feb718963e1"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text "></a><p></p><h2 xmlns="">7 WARNINGS AND PRECAUTIONS</h2><p xmlns="" class="First"> sample text </p><div class="Section" data-sectionCode="60023" id="e7f348e6-c9c4-43d5-950e-2a754092a1fa"><a name="e7f348e6-c9c4-43d5-950e-2a754092a1fa"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text "></a><p></p><h3 xmlns="">7.1 SPECIAL POPULATIONS</h3><p xmlns="" class="First"> sample text </p><div class="Section" data-sectionCode="60024" id="e94dc526-7275-40e3-8386-c43f0018b303"><a name="e94dc526-7275-40e3-8386-c43f0018b303"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1.1 PREGNANT WOMEN sample text "></a><p></p><h4 xmlns="">7.1.1 PREGNANT WOMEN</h4><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60025" id="a63c33a5-e08a-472c-b8a2-b12dbd115f7a"><a name="a63c33a5-e08a-472c-b8a2-b12dbd115f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1.2 BREAST-FEEDING sample text "></a><p></p><h4 xmlns="">7.1.2 BREAST-FEEDING</h4><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60026" id="db71c420-7743-43da-8386-5463a89b0f93"><a name="db71c420-7743-43da-8386-5463a89b0f93"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1.3 PEDIATRICS sample text "></a><p></p><h4 xmlns="">7.1.3 PEDIATRICS</h4><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60027" id="ee781ef0-be0c-406f-95f9-1122d8bf9968"><a name="ee781ef0-be0c-406f-95f9-1122d8bf9968"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 7.1.4 GERIATRICS sample text "></a><p></p><h4 xmlns="">7.1.4 GERIATRICS</h4><p xmlns="" class="First"> sample text </p></div></div></div><div class="Section" data-sectionCode="60028" id="fa8186fe-cc41-11e9-a32f-2a2ae2dbcce4"><a name="fa8186fe-cc41-11e9-a32f-2a2ae2dbcce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text "></a><p></p><h2 xmlns="">8 ADVERSE REACTIONS</h2><p xmlns="" class="First"> sample text </p><div class="Section" data-sectionCode="60029" id="b238395c-cc41-11e9-a32f-2a2ae2dbdce4"><a name="b238395c-cc41-11e9-a32f-2a2ae2dbdce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text "></a><p></p><h3 xmlns="">8.1 ADVERSE REACTION OVERVIEW</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60030" id="a98b942a-cc41-11e9-a32f-2a2ae2dbcce4"><a name="a98b942a-cc41-11e9-a32f-2a2ae2dbcce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text "></a><p></p><h3 xmlns="">8.2 CLINICAL TRIAL ADVERSE REACTIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60031" id="a0065926-cc41-11e9-a32f-2a2ae2dbcce4"><a name="a0065926-cc41-11e9-a32f-2a2ae2dbcce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text "></a><p></p><h3 xmlns="">8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60032" id="a6d30f16-cc41-11e9-a32f-2a2ae2dbcce4"><a name="a6d30f16-cc41-11e9-a32f-2a2ae2dbcce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text "></a><p></p><h3 xmlns="">8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60033" id="a63c33a5-e08a-473c-b8a2-b32dbd215f7a"><a name="a63c33a5-e08a-473c-b8a2-b32dbd215f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text "></a><p></p><h3 xmlns="">8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS)</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60034" id="c2b713f2-cc40-11e9-a32f-2a2ae2dbcce4"><a name="c2b713f2-cc40-11e9-a32f-2a2ae2dbcce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text "></a><p></p><h3 xmlns="">8.6 POST-MARKET ADVERSE REACTIONS</h3><p xmlns="" class="First"> sample text </p></div></div><div class="Section" data-sectionCode="60035" id="f3daf956-cc41-11e9-a32f-2a2ae2dbcce4"><a name="f3daf956-cc41-11e9-a32f-2a2ae2dbcce4"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text "></a><p></p><h2 xmlns="">9 DRUG INTERACTIONS</h2><p xmlns="" class="First"> sample text </p><div class="Section" data-sectionCode="60036" id="be75cfb9-3131-4903-800b-267527398a13"><a name="be75cfb9-3131-4903-800b-267527398a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text "></a><p></p><h3 xmlns="">9.1 SERIOUS DRUG INTERACTIONS BOX</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60037" id="a63c33a5-e08a-473c-b8a2-b14dbd315f7a"><a name="a63c33a5-e08a-473c-b8a2-b14dbd315f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.2 OVERVIEW sample text "></a><p></p><h3 xmlns="">9.2 OVERVIEW</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60038" id="a63c33a5-e08a-473c-b8d2-b14dbd315f7a"><a name="a63c33a5-e08a-473c-b8d2-b14dbd315f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.3 DRUG-DRUG INTERACTIONS sample text "></a><p></p><h3 xmlns="">9.3 DRUG-DRUG INTERACTIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60039" id="a63c33a5-e0aa-473c-b8a2-b14dbd315f7a"><a name="a63c33a5-e0aa-473c-b8a2-b14dbd315f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text "></a><p></p><h3 xmlns="">9.4 DRUG-FOOD INTERACTIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60040" id="a63c33a5-e08a-47bc-b8d2-b14dbd315f7a"><a name="a63c33a5-e08a-47bc-b8d2-b14dbd315f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text "></a><p></p><h3 xmlns="">9.5 DRUG-HERB INTERACTIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60041" id="be78cfb9-3131-4903-800b-267527398a13"><a name="be78cfb9-3131-4903-800b-267527398a13"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text "></a><p></p><h3 xmlns="">9.6 DRUG-LABORATORY TEST INTERACTIONS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60042" id="a63c33a5-e0aa-473c-b8a2-b14dcd315f7a"><a name="a63c33a5-e0aa-473c-b8a2-b14dcd315f7a"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text "></a><p></p><h3 xmlns="">9.7 DRUG-LIFESTYLE INTERACTIONS</h3><p xmlns="" class="First"> sample text </p></div></div><div class="Section" data-sectionCode="60043" id="fa324c26-b939-4c3a-901d-516ccc314522"><a name="fa324c26-b939-4c3a-901d-516ccc314522"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text "></a><p></p><h2 xmlns="">10 ACTION AND CLINICAL PHARMACOLOGY</h2><p xmlns="" class="First"> sample text </p><div class="Section" data-sectionCode="60044" id="aa324c26-b939-4c3a-901e-516ccc314522"><a name="aa324c26-b939-4c3a-901e-516ccc314522"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 10.1 MECHANISM OF ACTION sample text "></a><p></p><h3 xmlns="">10.1 MECHANISM OF ACTION</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60045" id="da324c26-b939-4d3a-901e-516ccc314522"><a name="da324c26-b939-4d3a-901e-516ccc314522"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 10.2 PHARMACODYNAMICS sample text "></a><p></p><h3 xmlns="">10.2 PHARMACODYNAMICS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60046" id="ba324c26-b939-4d4a-901e-516ccc314522"><a name="ba324c26-b939-4d4a-901e-516ccc314522"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 10.3 PHARMACOKINETICS sample text "></a><p></p><h3 xmlns="">10.3 PHARMACOKINETICS</h3><p xmlns="" class="First"> sample text </p></div></div><div class="Section" data-sectionCode="60047" id="aa324d26-c939-443a-901e-526dcc314522"><a name="aa324d26-c939-443a-901e-526dcc314522"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text "></a><p></p><h2 xmlns="">11 STORAGE, STABILITY AND DISPOSAL</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60048" id="aa325d26-c939-443a-901e-526dcc314522"><a name="aa325d26-c939-443a-901e-526dcc314522"></a><a name="section-ART I: HEALTH PROFESSIONAL INFORMATION1 INDICATIONS sample text %0A%09%09%09%091.1 PEDIATRICS TWYNSTA (telmisartan/amlodipine besylate) is indicated for treatment%0A                      of mild to moderate essential hypertension for whom combination therapy is%0A                      appropriate.  TWYNSTA is not indicated for initial therapy (see DOSAGE AND%0A                        ADMINISTRATION). Patients should be titrated on individual drugs. If the fixed dose%0A                      combination represents the dose and dosing frequency determined by this%0A                      titration, the use of TWYNSTA may be more convenient in the management of%0A                      patients. If during maintenance therapy dosage adjustment is necessary, it is%0A                      advisable to use the individual drugs. Geriatrics: No dose adjustment is necessary for elderly patients. It should be%0A                      recognized, however, that greater sensitivity in some older individuals cannot%0A                      be ruled out. Pediatrics (< 18 years of age):%0A                      TWYNSTA is not recommended for use in patients aged below 18 years due to a%0A                      lack of data on safety and efficacy. 1.2 GERIATRICSsample text2 CONTRAINDICATIONS sample text 3 SERIOUS WARNINGS AND PRECAUTIONS BOXSerious Warnings and PrecautionsWhen used in pregnancy, angiotensin receptor (AT1)%0A                          blockers (ARB) can cause injury or even death of the developing fetus.%0A                          When pregnancy is detected, TWYNSTA should be discontinued as soon as%0A                          possible (see WARNINGS AND PRECAUTIONS, Special Populations). General A case of rare but fatal angioedema had occurred in a patient who%0A                  had been medicated for about 6 months with telmisartan, one of the active%0A                  components of TWYNSTA. The Autopsy Report described evidence of edema of the%0A                  laryngeal mucosa, with terminal respiratory and circulatory failure. This is in%0A                  the context of approximately 5.2 million patient-years exposure to telmisartan%0A                  annually.  If laryngeal stridor or angioedema of the face, extremities,%0A                  lips, tongue, or glottis occurs, TWYNSTA should be discontinued immediately, the%0A                  patient treated appropriately in accordance with accepted medical care, and%0A                  carefully observed until the swelling disappears. In instances where swelling is%0A                  confined to the face and lips, the condition generally resolves without treatment,%0A                  although antihistamines may be useful in relieving symptoms. Where there is%0A                  involvement of tongue, glottis, or larynx, likely to cause airway obstruction,%0A                  appropriate therapy (including, but not limited to 0.3 to 0.5 ml of subcutaneous%0A                  epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS - Post Marketing%0A                    Adverse Drug Reactions; Telmisartan).  Patients with a%0A                  known hypersensitivity (anaphylaxis) or angioedema to ARBs should not be treated%0A                  with TWYNSTA (see ADVERSE%0A                    REACTIONS, Clinical Trial Adverse Drug Reactions - Unknown Frequencies, Immune%0A                    System Disorders, Angioedema and ADVERSE REACTIONS - Post%0A                      Marketing Adverse Drug Reactions; Telmisartan).Beta-blocker withdrawal: TWYNSTA gives no%0A                  protection against the dangers of abrupt beta- blocker withdrawal and such%0A                  withdrawal should be done by the gradual reduction of the dose of beta-blocker.%0A                4 DOSAGE AND ADMINISTRATION sample text 4.1 DOSING CONSIDERATIONS sample text 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT sample text 4.3 ADMINISTRATIONsample text4.4 RECONSTITUTION sample text 4.5 MISSED DOSE sample text 5 OVERDOSAGE sample text 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGINGsample text7 WARNINGS AND PRECAUTIONS sample text 7.1 SPECIAL POPULATIONS sample text 7.1.1 PREGNANT WOMEN sample text 7.1.2 BREAST-FEEDING sample text 7.1.3 PEDIATRICS sample text 7.1.4 GERIATRICS sample text 8 ADVERSE REACTIONS sample text 8.1 ADVERSE REACTION OVERVIEW sample text 8.2 CLINICAL TRIAL ADVERSE REACTIONS sample text 8.3 LESS COMMON CLINICAL TRIAL ADVERSE REACTIONS sample text 8.4 ABNORMAL LABORATORY FINDINGS: HEMATOLOGIC sample text 8.5 CLINICAL TRIAL ADVERSE REACTIONS (PEDIATRICS) sample text 8.6 POST-MARKET ADVERSE REACTIONS sample text 9 DRUG INTERACTIONS sample text 9.1 SERIOUS DRUG INTERACTIONS BOX sample text 9.2 OVERVIEW sample text 9.3 DRUG-DRUG INTERACTIONS sample text 9.4 DRUG-FOOD INTERACTIONS sample text 9.5 DRUG-HERB INTERACTIONS sample text 9.6 DRUG-LABORATORY TEST INTERACTIONS sample text 9.7 DRUG-LIFESTYLE INTERACTIONS sample text 10 ACTION AND CLINICAL PHARMACOLOGY sample text 10.1 MECHANISM OF ACTION sample text 10.2 PHARMACODYNAMICS sample text 10.3 PHARMACOKINETICS sample text 11 STORAGE, STABILITY AND DISPOSAL sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text 12 SPECIAL HANDLING INSTRUCTIONS sample text "></a><p></p><h2 xmlns="">12 SPECIAL HANDLING INSTRUCTIONS</h2><p xmlns="" class="First"> sample text </p></div></div></div></section><section class="card mb-2 pb-2" id="b6a947eb-e2be-45c0-8b2e-15d0d0eebed8"><h5 class="card-header text-white bg-aurora-accent1">PART II: SCIENTIFIC INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="60049" id="b6a947eb-e2be-45c0-8b2e-15d0d0eebed8"><a name="b6a947eb-e2be-45c0-8b2e-15d0d0eebed8"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text "></a><p></p><h1 xmlns="">PART II: SCIENTIFIC INFORMATION</h1><div class="Section" data-sectionCode="60050" id="c2875272-8229-4c12-919e-827854dcd76a"><a name="c2875272-8229-4c12-919e-827854dcd76a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure"></a><p></p><h2 xmlns="">13 PHARMACEUTICAL INFORMATION</h2><p xmlns="" class="First"><span class="Bold">Drug Substance â Telmisartan</span><br><br> Proper name: telmisartan<br><br> Chemical name:
                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-
                  bi-1H-benzimidazol]-1'-yl)methyl] <br><br>Molecular formula and molecular mass:
                    C<span class="Sub">33</span>H<span class="Sub">30</span>N<span class="Sub">4</span>O<span class="Sub">2</span>, 514.63 <br><br>
                  Structural formula: <br><br><img alt="telmisartan structure" src="telmisartan-struct.jpg"><br><br> Physicochemical properties: <br><br> Description: <br> Telmisartan
                  is a white to off-white, odorless crystalline powder. It is practically insoluble
                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except
                  HCl) and soluble in strong base. <br><br> Polymorphism: <br> Exhibits two
                  different polymorphic modifications, Form A (thermodynamically more stable) and
                  form B, and a third pseudo polymorphic form. <br><br> Melting Point: <br>269 Â±
                  1oC (polymorphic Form A) <br> 183 Â± 1oC (polymorphic Form B) <br><br><span class="Bold">Drug Substance â Amlodipine Besylate</span><br><br> Proper name: amlodipine besylate <br><br> 3-Ethyl 5-methyl
                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-
                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate
                  <br><br>Molecular formula and molecular mass:
                    C<span class="Sub">20</span>H<span class="Sub">25</span>IN<span class="Sub">2</span>O<span class="Sub">5</span>.C<span class="Sub">6</span>H<span class="Sub">6</span>O<span class="Sub">3</span>S,
                  514.63 <br><br> Structural formula: <br><br><img alt="amlodipine structure" src="amlodipine-struct.jpg"><br><br> Physicochemical properties: <br><br> Physical Form:<br> Amlodipine
                  besylate is a white crystalline substance.<br><br> Polymorphism: <br> Exhibits
                  two different polymorphic modifications, Form A (thermodynamically more stable)
                  and form B, and a third pseudo polymorphic form. <br><br> Solubility: <br>
                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,
                  M.P.= 203 C with decomposition. <br> pKa = 9.02 at 23.5<span class="Sup">o</span>C.
                </p></div><div class="Section" data-sectionCode="60051" id="a3287527-8229-4c12-919e-827854ddd76a"><a name="a3287527-8229-4c12-919e-827854ddd76a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure"></a><p></p><h2 xmlns="">14 CLINICAL TRIALS</h2><p xmlns="" class="First"> In a single 8-week multicenter, randomised, double-blind,
                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated
                  diastolic blood pressure â¥95 and &lt;119 mmHg in which subjects were treated with
                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its
                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and
                  T80+A10 mg), the combination treatments showed significant dose related reductions
                  in systolic and diastolic blood pressure from baseline values. Limited data was
                  available in subjects with severe hypertension.<br><br><span class="Bold">Study demographics and trial design</span><br><br>
                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)
                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)
                  of patients â¥65 years old. The majority of patients had a duration of hypertension
                  &gt;5 years [&lt;1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806
                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed
                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive
                  monotherapy, and 623 (42.6%) previously treated with combination therapy of â¥2
                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3
                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal
                  impairment. <br><br> The primary endpoint of this study was the change from
                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after
                  8 weeks of treatment. <br><br><span class="Bold">Results</span><br><br> Treatment with each
                  combination dose of TWYNSTA resulted in significantly greater diastolic and
                  systolic blood pressure reductions and higher control rates compared to the
                  respective monotherapy components. The telmisartan/amlodipine combinations showed
                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the
                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: </p><a xmlns="" name="t12842122"></a><table xmlns="" border="0" cellpadding="1" cellspacing="0" width="80%"><caption><span>Table 5: Placebo-Subtracted Mean Change from Baseline in Seated
                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy
                    Components</span></caption><tbody class="Headless"><tr class="First"><td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top">Amlodipine, mg</td><td class="Botrule Lrule Rrule Toprule" colspan="3">Telmisartan, mg</td></tr><tr><td class="Botrule Lrule Rrule Toprule">0</td><td class="Botrule Lrule Rrule Toprule">40</td><td class="Botrule Lrule Rrule Toprule">80</td></tr><tr><td class="Botrule Lrule Rrule Toprule">0</td><td class="Botrule Lrule Rrule Toprule">â</td><td class="Botrule Lrule Rrule Toprule">-12.1/-7.2</td><td class="Botrule Lrule Rrule Toprule">-11.8/-7.8</td></tr><tr><td class="Botrule Lrule Rrule Toprule">5</td><td class="Botrule Lrule Rrule Toprule">-12.9/-7.2</td><td class="Botrule Lrule Rrule Toprule">-19.3/-10.3</td><td class="Botrule Lrule Rrule Toprule">-19.6/-12.0</td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule">10</td><td class="Botrule Lrule Rrule Toprule">-18.2/-10.9</td><td class="Botrule Lrule Rrule Toprule">-22.2/-14.0</td><td class="Botrule Lrule Rrule Toprule">-23.9/-13.9</td></tr></tbody></table><a xmlns="" name="t5"></a><table xmlns="" border="0" width="80%" frame="void" rules="none"><caption><span>Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination
                    Therapy vs Monotherapy</span></caption><colgroup><col span="4"></colgroup><tfoot><tr class="First Last"><td colspan="4">*p&lt;0.05<br><span class="Sup">1</span>Mean change from baseline at Week 8 in seated systolic/diastolic
                        blood pressure</td></tr></tfoot><tbody class="Headless"><tr class="First"><td class="Botrule Lrule Rrule Toprule">Treatment Group</td><td class="Botrule Lrule Rrule Toprule">Mean Change<span class="Sup">1</span></td><td class="Botrule Lrule Rrule Toprule">Difference from amlodipine 5
                        mg</td><td class="Botrule Lrule Rrule Toprule">Difference from amlodipine 10
                        mg</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Twynsta 40/5 mg; n=270</td><td class="Botrule Lrule Rrule Toprule">-13.6 / -9.4</td><td class="Botrule Lrule Rrule Toprule">-7.4* / -3.6*</td><td class="Botrule Lrule Rrule Toprule">-2.4* / -1.4*</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Twynsta 80/5 mg; n=271</td><td class="Botrule Lrule Rrule Toprule">-15.0 / -10.6</td><td class="Botrule Lrule Rrule Toprule">-8.8* / -4.9*</td><td class="Botrule Lrule Rrule Toprule">-3.9* / -2.7*</td></tr><tr><td class="Botrule Lrule Rrule Toprule">Amlodipine 5 mg; n=255</td><td class="Botrule Lrule Rrule Toprule">-6.2 / -5.7</td><td class="Botrule Lrule Rrule Toprule">----</td><td class="Botrule Lrule Rrule Toprule">----</td></tr><tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left">Amlodipine 10 mg;
                        n=261</td><td class="Botrule Lrule Rrule Toprule">-11.1 / -8.0</td><td class="Botrule Lrule Rrule Toprule">----</td><td class="Botrule Lrule Rrule Toprule">----</td></tr></tbody></table><div class="Section" data-sectionCode="60052" id="e3287527-8229-4c12-919e-827854ddd78a"><a name="e3287527-8229-4c12-919e-827854ddd78a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text "></a><p></p><h3 xmlns="">14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60053" id="a2875272-8229-4c12-919e-827854ddd78a"><a name="a2875272-8229-4c12-919e-827854ddd78a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure14.2 STUDY RESULTS sample text "></a><p></p><h3 xmlns="">14.2 STUDY RESULTS</h3><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60054" id="a4287527-8229-4c12-919e-827954ddd78a"><a name="a4287527-8229-4c12-919e-827954ddd78a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure"></a><p></p><h3 xmlns="">14.3 COMPARATIVE BIOAVAILABILITY STUDIES</h3><p xmlns="" class="First"> sample text </p></div></div><div class="Section" data-sectionCode="60055" id="a2875272-8229-4c12-a19e-827954ddd78a"><a name="a2875272-8229-4c12-a19e-827954ddd78a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 15 MICROBIOLOGY sample text "></a><p></p><h2 xmlns="">15 MICROBIOLOGY</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60056" id="a42a7527-8229-4c12-a19e-827954ddd78a"><a name="a42a7527-8229-4c12-a19e-827954ddd78a"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 16 NON-CLINICAL TOXICOLOGY sample text "></a><p></p><h2 xmlns="">16 NON-CLINICAL TOXICOLOGY</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60057" id="b8a4d498-0fc3-4e44-b4b6-550140d4de5d"><a name="b8a4d498-0fc3-4e44-b4b6-550140d4de5d"></a><a name="section-ART II: SCIENTIFIC INFORMATION13 PHARMACEUTICAL INFORMATIONDrug Substance %E2%80%93 Telmisartan Proper name: telmisartan Chemical name:%0A                  [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'- dimethyl-2'- propyl[2,6'-%0A                  bi-1H-benzimidazol]-1'-yl)methyl] Molecular formula and molecular mass:%0A                    C33H30N4O2, 514.63 %0A                  Structural formula:  Physicochemical properties:  Description:  Telmisartan%0A                  is a white to off-white, odorless crystalline powder. It is practically insoluble%0A                  in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except%0A                  HCl) and soluble in strong base.  Polymorphism:  Exhibits two%0A                  different polymorphic modifications, Form A (thermodynamically more stable) and%0A                  form B, and a third pseudo polymorphic form.  Melting Point: 269 %C2%B1%0A                  1oC (polymorphic Form A)  183 %C2%B1 1oC (polymorphic Form B) Drug Substance %E2%80%93 Amlodipine Besylate Proper name: amlodipine besylate  3-Ethyl 5-methyl%0A                  (4RS)-2[(2-aminoethoxy)methyl]-4-(2-%0A                  chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate%0A                  Molecular formula and molecular mass:%0A                    C20H25IN2O5.C6H6O3S,%0A                  514.63  Structural formula:  Physicochemical properties:  Physical Form: Amlodipine%0A                  besylate is a white crystalline substance. Polymorphism:  Exhibits%0A                  two different polymorphic modifications, Form A (thermodynamically more stable)%0A                  and form B, and a third pseudo polymorphic form.  Solubility: %0A                  Amlodipine besylate is slightly soluble in water and sparingly soluble in ethanol,%0A                  M.P.= 203 C with decomposition.  pKa = 9.02 at 23.5oC.%0A                telmisartan structureamlodipine structure14 CLINICAL TRIALS In a single 8-week multicenter, randomised, double-blind,%0A                  placebo-controlled, parallel group factorial study, 1461 patients with mean seated%0A                  diastolic blood pressure %E2%89%A595 and <119 mmHg in which subjects were treated with%0A                  combination doses of TWYNSTA (telmisartan [T] and amlodipine [A] or its%0A                  monotherapy components, including T/A doses of T40+A5, T40+A10, T80+A5, and%0A                  T80+A10 mg), the combination treatments showed significant dose related reductions%0A                  in systolic and diastolic blood pressure from baseline values. Limited data was%0A                  available in subjects with severe hypertension.Study demographics and trial design%0A                  Overall, 737 (50.4%) patients were male; 1160 (79.4%) Caucasian, 237 (16.2%)%0A                  black, and 64 (4.4%) Asian. The overall mean age was 53.1 years with 205 (14.0%)%0A                  of patients %E2%89%A565 years old. The majority of patients had a duration of hypertension%0A                  &gt;5 years [<1 year: 206 (14.1%), 1-5 years: 446 (30.5%), &gt;5 years: 806%0A                  (55.2%), missing: 3 (0.2%)] with 307 (21.0%) not being previously prescribed%0A                  antihypertensive medication, 531 (36.3%) previously treated with antihypertensive%0A                  monotherapy, and 623 (42.6%) previously treated with combination therapy of %E2%89%A52%0A                  antihypertensive medications. The overall mean body mass index (BMI) was 31.3%0A                  kg/m2 with 238 (16.3%) of patients being diabetic and 12 (0.8%) with renal%0A                  impairment.  The primary endpoint of this study was the change from%0A                  baseline in the in-clinic seated trough cuff diastolic blood pressure (DBP) after%0A                  8 weeks of treatment. Results Treatment with each%0A                  combination dose of TWYNSTA resulted in significantly greater diastolic and%0A                  systolic blood pressure reductions and higher control rates compared to the%0A                  respective monotherapy components. The telmisartan/amlodipine combinations showed%0A                  dose-related reductions in systolic/diastolic blood pressure (SBP/DBP) across the%0A                  therapeutic dose range versus telmisartan monotherapy or amlodipine monotherapy: Table 5: Placebo-Subtracted Mean Change from Baseline in Seated%0A                    Systolic/Diastolic Blood Pressure (mmHg): Combination Therapy vs Monotherapy%0A                    ComponentsAmlodipine, mgTelmisartan, mg040800%E2%80%94-12.1/-7.2-11.8/-7.85-12.9/-7.2-19.3/-10.3-19.6/-12.010-18.2/-10.9-22.2/-14.0-23.9/-13.9Table 6: Effect on Seated Systolic/Diastolic Blood Pressure: Combination%0A                    Therapy vs Monotherapy*p<0.051Mean change from baseline at Week 8 in seated systolic/diastolic%0A                        blood pressureTreatment GroupMean Change1Difference from amlodipine 5%0A                        mgDifference from amlodipine 10%0A                        mgTwynsta 40/5 mg; n=270-13.6 / -9.4-7.4* / -3.6*-2.4* / -1.4*Twynsta 80/5 mg; n=271-15.0 / -10.6-8.8* / -4.9*-3.9* / -2.7*Amlodipine 5 mg; n=255-6.2 / -5.7--------Amlodipine 10 mg;%0A                        n=261-11.1 / -8.0--------14.1 TRIAL DESIGN AND STUDY DEMOGRAPHICS sample text 14.2 STUDY RESULTS sample text 14.3 COMPARATIVE BIOAVAILABILITY STUDIES sample text Chemical structure15 MICROBIOLOGY sample text 16 NON-CLINICAL TOXICOLOGY sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text 17 SUPPORTING PRODUCT MONOGRAPHS sample text "></a><p></p><h2 xmlns="">17 SUPPORTING PRODUCT MONOGRAPHS</h2><p xmlns="" class="First"> sample text </p></div></div></div></section><section class="card mb-2 pb-2" id="baa4d498-0fc3-4e44-b4b6-550140d4de5d"><h5 class="card-header text-white bg-aurora-accent1">PART III: PATIENT MEDICATION INFORMATION</h5><div class="spl"><div xmlns="http://www.w3.org/1999/xhtml" class="Section" data-sectionCode="60058" id="baa4d498-0fc3-4e44-b4b6-550140d4de5d"><a name="baa4d498-0fc3-4e44-b4b6-550140d4de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 "></a><p></p><h1 xmlns="">PART III: PATIENT MEDICATION INFORMATION</h1><div class="Section" data-sectionCode="60059" id="baa4d498-0fc3-4e44-b4b6-550140dde5d"><a name="baa4d498-0fc3-4e44-b4b6-550140dde5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 BRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA."></a><p></p><h2 xmlns="">BRAND NAME</h2><p xmlns="" class="First"><span class="Sup">Pr</span> Twynsta <span class="Sup">Â®</span><br>(Telmisartan/Amlodipine (as Amlodipine
                  Besylate)) Tablets<br><br> Read this carefully before you start taking TWYNSTA
                  and each time you get a refill. This leaflet is a summary and will not tell you
                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your
                  medical condition and treatment and ask if there is any new information about
                  TWYNSTA.</p></div><div class="Section" data-sectionCode="60060" id="baa4d498-0fc3-4e44-b4b6-550140d4e5d"><a name="baa4d498-0fc3-4e44-b4b6-550140d4e5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 PROPER NAME IN FINAL DOSAGE FORMS sample text "></a><p></p><h2 xmlns="">PROPER NAME IN FINAL DOSAGE FORMS</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60061" id="baa4d498-0gc3-4e44-bcb6-550140d4de5d"><a name="baa4d498-0gc3-4e44-bcb6-550140d4de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience."></a><p></p><h2 xmlns="">WHAT IS THIS MEDICATION USED FOR?</h2><p xmlns="" class="First">TWYNSTA is used to treat high blood pressure in patients who already
                  receive telmisartan and amlodipine from separate tablets and who wish to take
                  instead the same doses in one tablet for convenience.</p></div><div class="Section" data-sectionCode="60062" id="bca4d498-0gc3-4e44-bcb6-550140d4de5d"><a name="bca4d498-0gc3-4e44-bcb6-550140d4de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. "></a><p></p><h2 xmlns="">HOW DOES THIS MEDICATION WORK?</h2><p xmlns="" class="First"> TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: </p><ul xmlns=""><li>Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an
                    ARB because its medicinal ingredient ends in <span class="Bold">â-SARTANâ.</span></li><li>Amlodipine is a calcium channel blocker.</li></ul><p xmlns=""> These medicinal ingredients work together to lower blood pressure. This
                  medicine does not cure your disease. It helps to control it. Therefore, it is
                  important to continue taking TWYNSTA regularly even if you feel fine. </p></div><div class="Section" data-sectionCode="60063" id="bca4d498-0gc3-4e44-bcb6-55013024de5d"><a name="bca4d498-0gc3-4e44-bcb6-55013024de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                "></a><p></p><h2 xmlns="">WHAT ARE THE INGREDIENTS IN THIS MEDICATION?</h2><p xmlns="" class="First"> Telmisartan and amlodipine (as amlodipine besylate)<br><br> colloidal
                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric
                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline
                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.
                </p></div><div class="Section" data-sectionCode="60064" id="bca4d498-0gc3-4e54-bcb6-550130d4de5d"><a name="bca4d498-0gc3-4e54-bcb6-550130d4de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg."></a><p></p><h2 xmlns="">THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:</h2><p xmlns="" class="First">Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.</p></div><div class="Section" data-sectionCode="60065" id="bca4c498-0gc3-4e44-bcb6-550134d4de5d"><a name="bca4c498-0gc3-4e44-bcb6-550134d4de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. "></a><p></p><h2 xmlns="">DO NOT USE THIS MEDICATION IF:</h2><a xmlns="" name="t1"></a><table xmlns="" border="1" cellpadding="6" cellspacing="1" width="80%"><caption><span>Serious Warnings and Precautions - Pregnancy</span></caption><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> TWYNSTA
                        should not be used during pregnancy. If you discover that you are pregnant
                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or
                        pharmacist as soon as possible.</td></tr></tbody></table><ul xmlns=""><li> Have experienced an allergic reaction to any drug used to lower blood
                    pressure. </li><li> Have renal artery stenosis (narrowing of the blood vessels to one or both
                    kidneys). </li><li> Have swelling of your legs. </li><li> Have raised aldosterone levels (water and salt retention in the body along
                    with imbalance of various blood minerals). </li><li> Are taking a medicine that contains aliskiren, such as Rasilez, used to
                    lower high blood pressure. The combination with TWYNSTA is not recommended. </li><li> Are taking an angiotensin-converting-enzyme inhibitor (ACEI). </li><li> Have angina, narrowing of a heart valve or blood vessel, heart or blood
                    vessel disease. </li><li> Have diabetes mellitus, liver or kidney disease. </li><li> Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating. </li><li> Are on a low-salt diet. </li><li> Are taking a salt substitute that contains potassium, potassium
                    supplements, or a potassium-sparing diuretic (a specific kind of âwater pillâ
                    that makes your body keep potassium). </li><li> Are less than 18 years old. </li></ul><p xmlns="" class="First"> In case of surgery or anaesthesia, you should tell your doctor that you
                  are taking TWYNSTA.<br><br> If you take TWYNSTA together with a drug known as
                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly
                  stop using the beta-blocker. If your doctor advises you to discontinue use of the
                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,
                  before stopping it completely. <br><br><span class="Bold">Sorbitol:</span><br> Sorbitol is a source of
                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each
                  tablet. <br><br><span class="Bold">Driving and using machines:</span><br> Before you
                  perform tasks which may require special attention, wait until you know how you
                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur
                  after the first dose and when the dose is increased. </p></div><div class="Section" data-sectionCode="60066" id="b6b37351-bbc9-46d9-b148-27ba3cb0a75e"><a name="b6b37351-bbc9-46d9-b148-27ba3cb0a75e"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text "></a><p></p><h2 xmlns="">TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU:</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60067" id="edac0d6f-3c91-48b5-99c0-e0f940925d37"><a name="edac0d6f-3c91-48b5-99c0-e0f940925d37"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text "></a><p></p><h2 xmlns="">OTHER WARNINGS YOU SHOULD KNOW ABOUT:</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60068" id="f040bb1e-8989-42c8-82dc-53a855e88f0f"><a name="f040bb1e-8989-42c8-82dc-53a855e88f0f"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample text"></a><p></p><h2 xmlns="">TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.</h2><p xmlns="" class="First">Sample text</p></div><div class="Section" data-sectionCode="60069" id="bca40498-0gc3-4e44-bcb6-550134d4de5d"><a name="bca40498-0gc3-4e44-bcb6-550134d4de5d"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 THE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. "></a><p></p><h2 xmlns="">THE FOLLOWING MAY INTERACT WITH THIS MEDICATION:</h2><p xmlns="" class="First"> As with most medicines, interactions with other drugs are possible. Tell
                  your doctor, nurse, or pharmacist about all the medicines you take, including
                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or
                  alternative medicines. <br><br>The following may interact with TWYNSTA: </p><ul xmlns=""><li>Agents increasing serum potassium, such as a salt substitute that contains
                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific
                    kind of âwater pillâ);</li><li>Blood pressure lowering drugs, including diuretics (âwater</li><li>pillsâ), aliskiren-containing products (e.g. Rasilez), or
                    angiotensin-converting-enzyme inhibitors (ACEI);</li><li>Clarithromycin and Erythromycin, antibiotics used to treat
                    infections;</li><li>Lithium used to treat bipolar disease;</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and
                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and
                    celecoxib;</li><li>Corticosteroids taken by mouth or injection;</li><li>Digoxin to treat heart conditions;</li><li>Warfarin used to prevent blood clots (blood thinner);</li><li>Anticonvulsant agents. Examples include carbamazepine, phenobarbital,
                    phenytoin, fosphenytoin, primidone;</li><li>Rifampicin, an antibiotic used to treat infections;</li><li>Medicines used to treat HIV/AIDS. An example is ritonavir;</li><li>Medicines used to treat fungal infections. Examples include ketoconazole,
                    itraconazole;</li><li>Atorvastatin and simvastatin used to lower cholesterol;</li><li>Sildenafil (Viagra);</li><li>St. Johnâs Wort;</li><li>Beta-blockers;</li><li>Diltiazem;</li><li>Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,
                    temsirolimus and everolimus;</li><li>Immunosuppressants, such as cyclosporine and tacrolimus.</li></ul><p xmlns=""> Lower than normal blood pressure may occur when TWYNSTA is given with
                  the following: </p><ul xmlns=""><li> alcohol; </li><li> antidepressants; </li><li> barbiturates (sleeping pills); </li><li> narcotics (strong pain medications); </li><li> nitroglycerin or other nitrates. </li></ul></div><div class="Section" data-sectionCode="60070" id="e23321cd-5111-4aa3-b650-74f93bcda261"><a name="e23321cd-5111-4aa3-b650-74f93bcda261"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. "></a><p></p><h2 xmlns="">HOW TO TAKE THIS MEDICATION:</h2><p xmlns="" class="First"> Take TWYNSTA exactly as prescribed. It is recommended to swallow your
                  dose whole with water at about the same time everyday, preferably in the
                  morning.<br><br> Take TWYNSTA with or without food, but it should be taken the
                  same way each day.<br><br> Remove your TWYNSTA tablet from the blister just
                  prior to intake. </p></div><div class="Section" data-sectionCode="60071" id="cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7"><a name="cd0892a2-0e32-4fb7-9cc9-1bbfff60dee7"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. "></a><p></p><h2 xmlns="">USUAL DOSE:</h2><p xmlns="" class="First"> The usual dose of TWYNSTA is one tablet once a day. <br><br> If your
                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10
                  mg once daily. </p></div><div class="Section" data-sectionCode="60072" id="beaaa5b8-6693-4d4c-a897-fa5c9562b1be"><a name="beaaa5b8-6693-4d4c-a897-fa5c9562b1be"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms."></a><p></p><h2 xmlns="">OVERDOSE:</h2><a xmlns="" name="t2"></a><table xmlns="" border="1" cellpadding="6" cellspacing="1" width="80%"><caption><span>Overdose</span></caption><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> If you
                        think you have taken too much TWYNSTA contact your doctor, nurse,
                        pharmacist, hospital emergency department or regional Poison Control Centre
                        immediately, even if there are no symptoms.</td></tr></tbody></table></div><div class="Section" data-sectionCode="60073" id="ffd59b8d-fe66-4d86-a54f-0613d4168199"><a name="ffd59b8d-fe66-4d86-a54f-0613d4168199"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. "></a><p></p><h2 xmlns="">MISSED DOSE:</h2><p xmlns="" class="First"> If you have forgotten to take your dose during the day, carry on with
                  the next one at the usual time. Do not double dose. </p></div><div class="Section" data-sectionCode="60074" id="cb61f530-b95a-4047-b8ea-861c5a7a05e8"><a name="cb61f530-b95a-4047-b8ea-861c5a7a05e8"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results."></a><p></p><h2 xmlns="">WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION?</h2><p xmlns="" class="First"> Side effects may include: </p><ul xmlns=""><li>dizziness, vertigo (feeling of spinning);</li><li>drowsiness, insomnia, fatigue;</li><li>urge to urinate during the night;</li><li>rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),
                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,
                    hair loss, skin discolouration, photosensitivity reaction;</li><li>toxic epidermal necrolysis;</li><li>diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,
                    flatulence, change of bowel habit;</li><li>taste abnormalities, enlarged gums;</li><li>dry mouth;</li><li>headache, migraine, anxiety, mood altered, ringing in the ears;</li><li>sleepiness, sleeplessness, tiredness;</li><li>back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,
                    hypertonia;</li><li>visual impairment, double vision (diplopia);</li><li>upper respiratory tract infections (e.g. sore throat, inflamed sinuses,
                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of
                    breath;</li><li>inability to obtain an erection;</li><li>enlarging of male breasts;</li><li>weight increased, weight decreased.</li></ul><p xmlns=""> If any of these affects you severely, tell your doctor, nurse or pharmacist.<br><br><span class="Bold">TWYNSTA can cause abnormal blood test results. Your
                    doctor will decide when to perform blood tests and will interpret the
                    results.</span></p></div><div class="Section" data-sectionCode="60075" id="ee37dfa5-6d8c-4490-b4a5-c6f2d73aa041"><a name="ee37dfa5-6d8c-4490-b4a5-c6f2d73aa041"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text "></a><p></p><h2 xmlns="">SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM</h2><p xmlns="" class="First"> sample text </p></div><div class="Section" data-sectionCode="60076" id="c9d75711-2ce9-451e-aa51-91026ec1555e"><a name="c9d75711-2ce9-451e-aa51-91026ec1555e"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. "></a><p></p><h2 xmlns="">STORAGE:</h2><p xmlns="" class="First">Keep out of reach and sight of children. <br><br> Do not use TWYNSTA
                  after the expiry date which is stated on the carton. The expiry date refers to the
                  last day of that month. <br><br> Store in the original package in order to
                  protect from moisture and light. <br><br> Store at 15 - 30Â°C.
                  <br><br>Medicines should not be disposed of via wastewater or household waste.
                  Ask your pharmacist how to dispose of medicines no longer required. These measures
                  will help to protect the environment. </p><a xmlns="" name="t3"></a><table xmlns="" border="1" cellpadding="6" cellspacing="1" width="80%"><tbody class="Headless"><tr class="First Last"><td><span class="Bold">Reporting Side Effects</span><br><br> You can report any suspected side effects associated with the use
                        of health products to Health Canada by: <ul><li>Visiting the Web page on Adverse Reaction Reporting
                            (https://www.canada.ca/en/health-canada/services/drugs-
                            health-products/medeffect-canada.html) for information on how to report
                            online, by mail or by fax; or </li><li> Calling toll-free at 1-866-234-2345. </li></ul><span class="Italics">NOTE: Contact your health professional if you
                          need information about how to manage your side effects. The Canada
                          Vigilance Program does not provide medical advice. </span></td></tr></tbody></table></div><div class="Section" data-sectionCode="60077" id="f6693e7a-21c9-492f-833b-4e8f3911d3a5"><a name="f6693e7a-21c9-492f-833b-4e8f3911d3a5"></a><a name="section-ART III: PATIENT MEDICATION INFORMATIONBRAND NAMEPr Twynsta %C2%AE(Telmisartan/Amlodipine (as Amlodipine%0A                  Besylate)) Tablets Read this carefully before you start taking TWYNSTA%0A                  and each time you get a refill. This leaflet is a summary and will not tell you%0A                  everything about TWYNSTA. Talk to your doctor, nurse, or pharmacist about your%0A                  medical condition and treatment and ask if there is any new information about%0A                  TWYNSTA.PROPER NAME IN FINAL DOSAGE FORMS sample text WHAT IS THIS MEDICATION USED FOR?TWYNSTA is used to treat high blood pressure in patients who already%0A                  receive telmisartan and amlodipine from separate tablets and who wish to take%0A                  instead the same doses in one tablet for convenience.HOW DOES THIS MEDICATION WORK? TWYNSTA contains a combination of 2 drugs, telmisartan and amlodipine: Telmisartan is an angiotensin receptor blocker (ARB). You can recognize an%0A                    ARB because its medicinal ingredient ends in %E2%80%9C-SARTAN%E2%80%9D.Amlodipine is a calcium channel blocker. These medicinal ingredients work together to lower blood pressure. This%0A                  medicine does not cure your disease. It helps to control it. Therefore, it is%0A                  important to continue taking TWYNSTA regularly even if you feel fine. WHAT ARE THE INGREDIENTS IN THIS MEDICATION? Telmisartan and amlodipine (as amlodipine besylate) colloidal%0A                  anhydrous silica, FD&amp;C blue No 1 aluminium lake, ferric oxide black, ferric%0A                  oxide yellow, magnesium stearate, maize starch, meglumine, microcrystalline%0A                  cellulose, povidone K25, pregelatinized starch, sodium hydroxide, sorbitol.%0A                THIS MEDICATION COMES IN THE FOLLOWING DOSAGE FORMS:Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg.DO NOT USE THIS MEDICATION IF:Serious Warnings and Precautions - Pregnancy TWYNSTA%0A                        should not be used during pregnancy. If you discover that you are pregnant%0A                        while taking TWYNSTA, stop the medication and contact your doctor, nurse, or%0A                        pharmacist as soon as possible. Have experienced an allergic reaction to any drug used to lower blood%0A                    pressure.  Have renal artery stenosis (narrowing of the blood vessels to one or both%0A                    kidneys).  Have swelling of your legs.  Have raised aldosterone levels (water and salt retention in the body along%0A                    with imbalance of various blood minerals).  Are taking a medicine that contains aliskiren, such as Rasilez, used to%0A                    lower high blood pressure. The combination with TWYNSTA is not recommended.  Are taking an angiotensin-converting-enzyme inhibitor (ACEI).  Have angina, narrowing of a heart valve or blood vessel, heart or blood%0A                    vessel disease.  Have diabetes mellitus, liver or kidney disease.  Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.  Are on a low-salt diet.  Are taking a salt substitute that contains potassium, potassium%0A                    supplements, or a potassium-sparing diuretic (a specific kind of %E2%80%9Cwater pill%E2%80%9D%0A                    that makes your body keep potassium).  Are less than 18 years old.  In case of surgery or anaesthesia, you should tell your doctor that you%0A                  are taking TWYNSTA. If you take TWYNSTA together with a drug known as%0A                  betablockers (e.g. acebutolol, atenolol, metoprolol, nadolol), do not suddenly%0A                  stop using the beta-blocker. If your doctor advises you to discontinue use of the%0A                  beta-blocker, your dose should be decreased slowly, as recommended by your doctor,%0A                  before stopping it completely. Sorbitol: Sorbitol is a source of%0A                  fructose. TWYNSTA tablets 40/5 mg and 40/10 mg contain 168.64 mg sorbitol in each%0A                  tablet. Driving and using machines: Before you%0A                  perform tasks which may require special attention, wait until you know how you%0A                  respond to TWYNSTA. Dizziness, lightheadedness, or fainting can especially occur%0A                  after the first dose and when the dose is increased. TO HELP AVOID SIDE EFFECTS AND ENSURE PROPER USE, TALK TO YOUR HEALTHCARE PROFESSIONAL BEFORE YOU TAKE MEDICATION. TALK ABOUT ANY HEALTH CONDITIONS OR PROBLEMS YOU MAY HAVE, INCLUDING IF YOU: sample text OTHER WARNINGS YOU SHOULD KNOW ABOUT: sample text TELL YOUR HEALTHCARE PROFESSIONAL ABOUT ALL THE MEDICINES YOU TAKE, INCLUDING ANY DRUGS, VITAMINS, MINERALS, NATURAL SUPPLEMENTS OR ALTERNATIVE MEDICINES.Sample textTHE FOLLOWING MAY INTERACT WITH THIS MEDICATION: As with most medicines, interactions with other drugs are possible. Tell%0A                  your doctor, nurse, or pharmacist about all the medicines you take, including%0A                  drugs prescribed by other doctors, vitamins, minerals, natural supplements, or%0A                  alternative medicines. The following may interact with TWYNSTA: Agents increasing serum potassium, such as a salt substitute that contains%0A                    potassium, potassium supplements, or a potassium-sparing diuretic (a specific%0A                    kind of %E2%80%9Cwater pill%E2%80%9D);Blood pressure lowering drugs, including diuretics (%E2%80%9Cwaterpills%E2%80%9D), aliskiren-containing products (e.g. Rasilez), or%0A                    angiotensin-converting-enzyme inhibitors (ACEI);Clarithromycin and Erythromycin, antibiotics used to treat%0A                    infections;Lithium used to treat bipolar disease;Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and%0A                    swelling. Examples include ASA (Aspirin), ibuprofen, naproxen, and%0A                    celecoxib;Corticosteroids taken by mouth or injection;Digoxin to treat heart conditions;Warfarin used to prevent blood clots (blood thinner);Anticonvulsant agents. Examples include carbamazepine, phenobarbital,%0A                    phenytoin, fosphenytoin, primidone;Rifampicin, an antibiotic used to treat infections;Medicines used to treat HIV/AIDS. An example is ritonavir;Medicines used to treat fungal infections. Examples include ketoconazole,%0A                    itraconazole;Atorvastatin and simvastatin used to lower cholesterol;Sildenafil (Viagra);St. John%E2%80%99s Wort;Beta-blockers;Diltiazem;Mechanistic Target of Rapamycin (mTOR) inhibitors, such as sirolimus,%0A                    temsirolimus and everolimus;Immunosuppressants, such as cyclosporine and tacrolimus. Lower than normal blood pressure may occur when TWYNSTA is given with%0A                  the following:  alcohol;  antidepressants;  barbiturates (sleeping pills);  narcotics (strong pain medications);  nitroglycerin or other nitrates. HOW TO TAKE THIS MEDICATION: Take TWYNSTA exactly as prescribed. It is recommended to swallow your%0A                  dose whole with water at about the same time everyday, preferably in the%0A                  morning. Take TWYNSTA with or without food, but it should be taken the%0A                  same way each day. Remove your TWYNSTA tablet from the blister just%0A                  prior to intake. USUAL DOSE: The usual dose of TWYNSTA is one tablet once a day.  If your%0A                  liver is not working properly, the usual dose should not exceed 40/5 mg or 40/10%0A                  mg once daily. OVERDOSE:Overdose If you%0A                        think you have taken too much TWYNSTA contact your doctor, nurse,%0A                        pharmacist, hospital emergency department or regional Poison Control Centre%0A                        immediately, even if there are no symptoms.MISSED DOSE: If you have forgotten to take your dose during the day, carry on with%0A                  the next one at the usual time. Do not double dose. WHAT ARE POSSIBLE SIDE EFFECTS FROM USING THIS MEDICATION? Side effects may include: dizziness, vertigo (feeling of spinning);drowsiness, insomnia, fatigue;urge to urinate during the night;rash, eczema, redness of skin, skin eruptions, itching, hives (urticaria),%0A                    scaling of the skin (dermatitis exfoliative), increased sweating, drug rash,%0A                    hair loss, skin discolouration, photosensitivity reaction;toxic epidermal necrolysis;diarrhea, vomiting, constipation, nausea, upset stomach, abdominal pain,%0A                    flatulence, change of bowel habit;taste abnormalities, enlarged gums;dry mouth;headache, migraine, anxiety, mood altered, ringing in the ears;sleepiness, sleeplessness, tiredness;back or leg pain, muscle cramps, joint pain, muscle spasms, joint swelling,%0A                    hypertonia;visual impairment, double vision (diplopia);upper respiratory tract infections (e.g. sore throat, inflamed sinuses,%0A                    common cold), flu-like illness, cough, sneezing, runny nose, shortness of%0A                    breath;inability to obtain an erection;enlarging of male breasts;weight increased, weight decreased. If any of these affects you severely, tell your doctor, nurse or pharmacist.TWYNSTA can cause abnormal blood test results. Your%0A                    doctor will decide when to perform blood tests and will interpret the%0A                    results.SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM sample text STORAGE:Keep out of reach and sight of children.  Do not use TWYNSTA%0A                  after the expiry date which is stated on the carton. The expiry date refers to the%0A                  last day of that month.  Store in the original package in order to%0A                  protect from moisture and light.  Store at 15 - 30%C2%B0C.%0A                  Medicines should not be disposed of via wastewater or household waste.%0A                  Ask your pharmacist how to dispose of medicines no longer required. These measures%0A                  will help to protect the environment. Reporting Side Effects You can report any suspected side effects associated with the use%0A                        of health products to Health Canada by: Visiting the Web page on Adverse Reaction Reporting%0A                            (https://www.canada.ca/en/health-canada/services/drugs-%0A                            health-products/medeffect-canada.html) for information on how to report%0A                            online, by mail or by fax; or  Calling toll-free at 1-866-234-2345. NOTE: Contact your health professional if you%0A                          need information about how to manage your side effects. The Canada%0A                          Vigilance Program does not provide medical advice. IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:If you want more information about TWYNSTA: Talk to your healthcare professional.  Find the full product monograph that is prepared for healthcare%0A                    professionals and includes this Consumer Information by visiting the Health%0A                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-%0A                    health-products/drug-products/drug-product-database.html), the manufacturer%E2%80%99s%0A                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,%0A                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633.  This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The%0A                  information in this leaflet is current up to the time of the last revision date%0A                  shown below, but more current information may be available from the%0A                  manufacturer. Last revised: August 7, 2019 "></a><p></p><h2 xmlns="">IF YOU WANT MORE INFORMATION ABOUT THIS MEDICATION:</h2><p xmlns="" class="First"><span class="Bold">If you want more information about TWYNSTA:</span></p><ul xmlns=""><li> Talk to your healthcare professional. </li><li> Find the full product monograph that is prepared for healthcare
                    professionals and includes this Consumer Information by visiting the Health
                    Canada website (https://www.canada.ca/en/health-canada/services/drugs-
                    health-products/drug-products/drug-product-database.html), the manufacturerâs
                    website (https://www.boehringer- ingelheim.ca), or by calling the manufacturer,
                    Boehringer Ingelheim (Canada) Ltd., at: 1-800-263-5103, ext. 84633. </li></ul><p xmlns=""> This leaflet was prepared by Boehringer Ingelheim (Canada) Ltd. The
                  information in this leaflet is current up to the time of the last revision date
                  shown below, but more current information may be available from the
                  manufacturer.<br><br> Last revised: August 7, 2019 </p></div></div></div></section><section class="hide-in-screen card" id="print-product-details"><h5 class="card-header text-white">PRODUCT DETAILS</h5><div class="spl"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Market Authorization Holder -&nbsp;</span>BOEHRINGER INGELHEIM (CANADA) LTD LTEE (3617)</td></tr><tr><th scope="col" class="formTitle">Contact Address</th><th scope="col" class="formTitle">Additional Contact Information</th></tr><tr class="formTableRowAlt"><td class="formItem"><table><tr><td>5180 South Service Road</td></tr><tr><td>Burlington,&nbsp;Ontario,&nbsp;L7L 5H4</td></tr><tr><td>CANADA</td></tr></table></td><td class="formItem"><div>Tel: +18002635103</div><div>Email: test@boehringer.ca</div><div>Web: https://www.boehringer-ingelheim.ca</div></td></tr></table><section><div class="Section"><p></p><h2>PRODUCT #1 TWYNSTA 
		(TELMISARTAN/AMLODIPINE), 		
		TELMISARTAN&nbsp;
			40&nbsp;
			MG&nbsp;
		/ AMLODIPINE&nbsp;
			5&nbsp;
			MG&nbsp;
		TABLET</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371022</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">40&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">5&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A1</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>1234<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #2 TWYNSTA 
		(TELMISARTAN/AMLODIPINE), 		
		TELMISARTAN&nbsp;
			40&nbsp;
			MG&nbsp;
		/ AMLODIPINE&nbsp;
			10&nbsp;
			MG&nbsp;
		TABLET</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371030</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">40&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">10&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A2</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>2<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #3 TWYNSTA 
		(TELMISARTAN/AMLODIPINE), 		
		TELMISARTAN&nbsp;
			80&nbsp;
			MG&nbsp;
		/ AMLODIPINE&nbsp;
			5&nbsp;
			MG&nbsp;
		TABLET</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371049</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">80&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">5&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A3</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>3<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section><section><div class="Section"><p></p><h2>PRODUCT #4 TWYNSTA 
		(TELMISARTAN/AMLODIPINE), 		
		TELMISARTAN&nbsp;
			80&nbsp;
			MG&nbsp;
		/ AMLODIPINE&nbsp;
			10&nbsp;
			MG&nbsp;
		TABLET</h2><table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="contentTableTitle"><strong>TWYNSTA&nbsp;		
					</strong><br><span class="contentTableReg">telmisartan/amlodipine tablet</span></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Brand Name</td><td class="formItem">Twynsta</td></tr><tr class="formTableRow"><td class="formLabel">Non-Proprietary Name</td><td class="formItem">telmisartan/amlodipine</td></tr><tr class="formTableRowAlt"><td class="formLabel">Drug Identification Number (DIN)</td><td class="formItem">02371057</td></tr><tr class="formTableRow"><td class="formLabel">Route of Administration</td><td class="formItem">ORAL USE</td></tr><tr class="formTableRowAlt"><td class="formLabel">Dosage Form</td><td class="formItem">TABLET</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Basis of Strength</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TELMISARTAN</strong> (11907)  (TELMISARTAN - 11907) </td><td class="formItem">TELMISARTAN</td><td class="formItem">80&nbsp;
			mg</td></tr><tr class="formTableRow"><td class="formItem"><strong>AMLODIPINE BESYLATE</strong> (1223)  (AMLODIPINE - 11344) </td><td class="formItem">AMLODIPINE</td><td class="formItem">10&nbsp;
			mg</td></tr></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr><tr><th class="formTitle" scope="col">Ingredient Name</th><th class="formTitle" scope="col">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>colloidal anhydrous silica</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FD&amp;C blue No 1</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>aluminium lake (E 133)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>erric oxide black (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>ferric oxide yellow (E172)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>magnesium stearate</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>maize starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>meglumine</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>microcrystalline cellulose</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>povidone K25</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>pregelatinized starch</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>sodium hydroxide</strong> (xx) </td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>sorbitol (E420)</strong> (xx) </td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody><tr><td class="formHeadingTitle" colspan="2">Product Characteristics</td></tr><tr class="formTableRow"><td class="formLabel">Product Type</td><td class="formItem">PHARMACEUTICAL</td></tr><tr class="formTableRowAlt"><td class="formLabel">Colour</td><td class="formItem">WHITE (white to off-white),&nbsp;BLUE (Blue)</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">OVAL (Oval)</td></tr><tr class="formTableRowAlt"><td class="formLabel">Size</td><td class="formItem">14mm</td></tr><tr class="formTableRow"><td class="formLabel">Score</td><td class="formItem">1</td></tr><tr class="formTableRowAlt"><td class="formLabel">Imprint</td><td class="formItem">A4</td></tr><tr class="formTableRow"><td class="formLabel">Flavour</td><td class="formItem"></td></tr><tr class="formTableRowAlt"><td class="formLabel">Combination Product</td><td class="formItem">NOT A COMBINATION PRODUCT</td></tr><tr class="formTableRow"><td class="formLabel">Pharmaceutical Standard</td><td class="formItem">MFR</td></tr><tr class="formTableRowAlt"><td class="formLabel">Schedule</td><td class="formItem">PRESCRIPTION</td></tr><tr class="formTableRow"><td class="formLabel">Therapeutic Class</td><td class="formItem">ANGIOTENSIN II RECEPTOR ANTAGONISTS,&nbsp;MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS</td></tr></tbody></table></td></tr><tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite"><tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr><tr><th scope="col" width="1" class="formTitle">#</th><th scope="col" class="formTitle">Package Identifier</th><th scope="col" class="formTitle">Package Description</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><th scope="row" class="formItem">1</th><td class="formItem">4567<br>4<br></td><td class="formItem">4 &nbsp;in&nbsp;1 BOX<br>7 &nbsp;in&nbsp;1 BLISTER<br></td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Regulatory Status</span></td></tr><tr><th scope="col" class="formTitle">Regulatory Activity Type</th><th scope="col" class="formTitle">Control Number</th><th scope="col" class="formTitle">Date of Approval</th><th scope="col" class="formTitle">Date of Cancellation</th></tr><tr class="formTableRowAlt"><td class="formItem">NDS</td><td class="formItem">225785</td><td class="formItem">2019-08-07</td><td class="formItem"></td></tr></table></td></tr></tbody></table></div></section></div></section></div></div></div></main></div></div>
<script src="https://code.jquery.com/jquery-3.4.1.slim.min.js" integrity="sha384-J6qa4849blE2+poT4WnyKhv5vZF5SrPo0iEjwBvKU7imGFAV0wwj1yYfoRSJoZ+n" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.0/dist/umd/popper.min.js" integrity="sha384-Q6E9RHvbIyZFJoft+2mJbHaEWldlvI9IOYy5n3zV9zzTtmI3UksdQRVvoxMfooAo" crossorigin="anonymous"></script>
<script src="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/js/bootstrap.min.js" integrity="sha384-wfSDF2E50Y2D1uUdj0O3uMBJnjuUD4Ih7YwaYd1iqfktj0Uod8GCExl3Og8ifwB6" crossorigin="anonymous"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/stickyfill/2.0.5/stickyfill.min.js"></script>
		<script xmlns="http://www.w3.org/1999/xhtml">
			try {
			  var elements = document.querySelectorAll('.sticky');
			  Stickyfill.add(elements);
			} catch (e) {
			  console.log(e)
			}
		</script></body></html>